Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study
We aimed to investigate which clinical and metabolic tests offer optimal accuracy and acceptability to help diagnose diabetes among a large sample of people with serious mental illness in receipt of antipsychotic medication. A prospective observational study design of biochemical and clinical factor...
Gespeichert in:
Veröffentlicht in: | PloS one 2019-09, Vol.14 (9), p.e0210674 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 9 |
container_start_page | e0210674 |
container_title | PloS one |
container_volume | 14 |
creator | Mitchell, Alex J Vancampfort, Davy Manu, Peter Correll, Christoph U Wampers, Martien van Winkel, Ruud Yu, Weiping De Hert, Marc |
description | We aimed to investigate which clinical and metabolic tests offer optimal accuracy and acceptability to help diagnose diabetes among a large sample of people with serious mental illness in receipt of antipsychotic medication.
A prospective observational study design of biochemical and clinical factors was used. Biochemical measures were fasting glucose, insulin and lipids, oral glucose tolerance testing (OGTT), hemoglobin A1c, and insulin resistance assessed with the homeostatic model (HOMA-IR) were determined in a consecutive cohort of 798 adult psychiatric inpatients receiving antipsychotics. Clinical variables were gender, age, global assessment of functioning (GAF), mental health clinicians' global impression (CGI), duration of severe mental illness, height, weight, BMI and waist/hip ratio. In addition, we calculated the risk using combined clinical predictors using the Leicester Practice Risk Score (LPRS) and the Topics Diabetes Risk Score (TDRS). Diabetes was defined by older criteria (impaired fasting glucose (IFG) or OGTT) as well as2010 criteria (IFG or OGTT or Glycated haemoglobin (HBA1c)) at conventional cut-offs.
Using the older criteria, 7.8% had diabetes (men: 6.3%; women: 10.3%). Using the new criteria, 10.2% had diabetes (men: 8.2%, women: 13.2%), representing a 30.7% increase (p = 0.02) in the prevalence of diabetes. Regarding biochemical predictors, conventional OGTT, IFG, and HbA1c thresholds used to identify newly defined diabetes missed 25%, 50% and 75% of people with diabetes, respectively. The conventional HBA1c cut-point of ≥6.5% (48 mmol/mol) missed 7 of 10 newly defined cases of diabetes while a cut-point of ≥5.7% improved sensitivity from 44.4% to up to 85%. Specific algorithm approaches offered reasonable accuracy. Unfortunately no single clinical factor was able to accurately rule-in a diagnosis of diabetes. Three clinical factors were able to rule-out diabetes with good accuracy namely: BMI, waist/hip ratio and height. A BMI < 30 had a 92% negative predictive value in ruling-out diabetes. Of those not diabetic, 20% had a BMI ≥ 30. However, for complete diagnosis a specific biochemical protocol is still necessary.
Patients with SMI maintained on antipsychotic medication cannot be reliably screened for diabetes using clinical variables alone. Accurate assessment requires a two-step algorithm consisting of HBA1c ≥5.7% followed by both FG and OGTT which does not require all patients to have OGTT and FG. |
doi_str_mv | 10.1371/journal.pone.0210674 |
format | Article |
fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2289570412</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A599263193</galeid><doaj_id>oai_doaj_org_article_3d0c41d9f4a840b1b181ce5338665303</doaj_id><sourcerecordid>A599263193</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-f7bc44ec7403b53d55cb3d6ace95fec62103108b0f7552b61344e0c8c53265a73</originalsourceid><addsrcrecordid>eNqNk9tq3DAQhk1padK0b1BaQaHQi91KluXDTUsIPQQCgR4vhSyP11q01lYjp82T9fU6u9mEXWih-MLW6Jt_5F8zWfZU8LmQlXi9DFMcjZ-vwwhzngteVsW97Fg0Mp-VOZf3976PskeIS86VrMvyYXYkhRJSNfVx9vv74OzArHejs8YzM3asdcEOsNqu1xE6Z1OIyHAIk6ddYBNCx1JgaCPAyPoQWedMCwmQuZGtTXIwJmQ_XRoYQnRhQraiEAk670dAZBEsuCs3Lqhkcmu8tkNIzhJG9UggjG_ZKfMmLoCFlkSutkFSwDR114-zB73xCE9275Ps6_t3X84-zi4uP5yfnV7MbNnkadZXrS0KsFXBZatkp5RtZVcaC43qwZZkmxS8bnlfKZW3pZBEc1tbJfNSmUqeZM9vdNc-oN55jjrP60ZVvBA5Eec3RBfMUq-jW5l4rYNxehsIcaFNpD_zoGXHbSG6pi9MXfBWtKIWFpTc3IqSXJLWm121qSUjLFkWjT8QPdwZ3aAX4UrT3eeFqkngxU4ghh8TYPrHkXfUwtCp3NgHErMrh1afqqbJS0mdQ9T8LxQ93aY3qOt6R_GDhFcHCcQk-JUWZkLU558__T97-e2QfbnHDmB8GjD4adMPeAgWN6CNATFCf-ec4HozNLdu6M3Q6N3QUNqzfdfvkm6nRP4B-10WCg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2289570412</pqid></control><display><type>article</type><title>Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Mitchell, Alex J ; Vancampfort, Davy ; Manu, Peter ; Correll, Christoph U ; Wampers, Martien ; van Winkel, Ruud ; Yu, Weiping ; De Hert, Marc</creator><contributor>McKenna, Peter John</contributor><creatorcontrib>Mitchell, Alex J ; Vancampfort, Davy ; Manu, Peter ; Correll, Christoph U ; Wampers, Martien ; van Winkel, Ruud ; Yu, Weiping ; De Hert, Marc ; McKenna, Peter John</creatorcontrib><description>We aimed to investigate which clinical and metabolic tests offer optimal accuracy and acceptability to help diagnose diabetes among a large sample of people with serious mental illness in receipt of antipsychotic medication.
A prospective observational study design of biochemical and clinical factors was used. Biochemical measures were fasting glucose, insulin and lipids, oral glucose tolerance testing (OGTT), hemoglobin A1c, and insulin resistance assessed with the homeostatic model (HOMA-IR) were determined in a consecutive cohort of 798 adult psychiatric inpatients receiving antipsychotics. Clinical variables were gender, age, global assessment of functioning (GAF), mental health clinicians' global impression (CGI), duration of severe mental illness, height, weight, BMI and waist/hip ratio. In addition, we calculated the risk using combined clinical predictors using the Leicester Practice Risk Score (LPRS) and the Topics Diabetes Risk Score (TDRS). Diabetes was defined by older criteria (impaired fasting glucose (IFG) or OGTT) as well as2010 criteria (IFG or OGTT or Glycated haemoglobin (HBA1c)) at conventional cut-offs.
Using the older criteria, 7.8% had diabetes (men: 6.3%; women: 10.3%). Using the new criteria, 10.2% had diabetes (men: 8.2%, women: 13.2%), representing a 30.7% increase (p = 0.02) in the prevalence of diabetes. Regarding biochemical predictors, conventional OGTT, IFG, and HbA1c thresholds used to identify newly defined diabetes missed 25%, 50% and 75% of people with diabetes, respectively. The conventional HBA1c cut-point of ≥6.5% (48 mmol/mol) missed 7 of 10 newly defined cases of diabetes while a cut-point of ≥5.7% improved sensitivity from 44.4% to up to 85%. Specific algorithm approaches offered reasonable accuracy. Unfortunately no single clinical factor was able to accurately rule-in a diagnosis of diabetes. Three clinical factors were able to rule-out diabetes with good accuracy namely: BMI, waist/hip ratio and height. A BMI < 30 had a 92% negative predictive value in ruling-out diabetes. Of those not diabetic, 20% had a BMI ≥ 30. However, for complete diagnosis a specific biochemical protocol is still necessary.
Patients with SMI maintained on antipsychotic medication cannot be reliably screened for diabetes using clinical variables alone. Accurate assessment requires a two-step algorithm consisting of HBA1c ≥5.7% followed by both FG and OGTT which does not require all patients to have OGTT and FG.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0210674</identifier><identifier>PMID: 31513598</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Algorithms ; Antipsychotic agents ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - therapeutic use ; Antipsychotics ; Biochemistry ; Biology and life sciences ; Biomarkers ; Criteria ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus - diagnosis ; Diabetes Mellitus - epidemiology ; Diabetes Mellitus - etiology ; Diabetes Mellitus - metabolism ; Diabetics ; Diagnosis ; Drug therapy ; Drugs ; Fasting ; Female ; Glucose ; Glucose - metabolism ; Glucose tolerance ; Glucose tolerance test ; Glycosylated hemoglobin ; Health ; Health risks ; Health screening ; Hemoglobin ; Hemoglobins ; Hip ; Hospital patients ; Humans ; Insulin ; Insulin resistance ; Laboratory testing ; Lipids ; Male ; Medical diagnosis ; Medicine and Health Sciences ; Mental disorders ; Mental Disorders - complications ; Mental Disorders - drug therapy ; Mental health ; Mentally ill persons ; Middle Aged ; Mortality ; Observational studies ; Phenotype ; Prevalence ; Prospective Studies ; Psychotropic drugs ; Reproducibility of Results ; Risk ; Risk assessment ; Risk factors ; ROC Curve ; Sensitivity and Specificity ; Systematic review ; Type 2 diabetes</subject><ispartof>PloS one, 2019-09, Vol.14 (9), p.e0210674</ispartof><rights>COPYRIGHT 2019 Public Library of Science</rights><rights>2019 Mitchell et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 Mitchell et al 2019 Mitchell et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-f7bc44ec7403b53d55cb3d6ace95fec62103108b0f7552b61344e0c8c53265a73</citedby><cites>FETCH-LOGICAL-c692t-f7bc44ec7403b53d55cb3d6ace95fec62103108b0f7552b61344e0c8c53265a73</cites><orcidid>0000-0001-6014-598X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742458/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742458/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,2096,2915,23847,27905,27906,53772,53774,79349,79350</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31513598$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>McKenna, Peter John</contributor><creatorcontrib>Mitchell, Alex J</creatorcontrib><creatorcontrib>Vancampfort, Davy</creatorcontrib><creatorcontrib>Manu, Peter</creatorcontrib><creatorcontrib>Correll, Christoph U</creatorcontrib><creatorcontrib>Wampers, Martien</creatorcontrib><creatorcontrib>van Winkel, Ruud</creatorcontrib><creatorcontrib>Yu, Weiping</creatorcontrib><creatorcontrib>De Hert, Marc</creatorcontrib><title>Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>We aimed to investigate which clinical and metabolic tests offer optimal accuracy and acceptability to help diagnose diabetes among a large sample of people with serious mental illness in receipt of antipsychotic medication.
A prospective observational study design of biochemical and clinical factors was used. Biochemical measures were fasting glucose, insulin and lipids, oral glucose tolerance testing (OGTT), hemoglobin A1c, and insulin resistance assessed with the homeostatic model (HOMA-IR) were determined in a consecutive cohort of 798 adult psychiatric inpatients receiving antipsychotics. Clinical variables were gender, age, global assessment of functioning (GAF), mental health clinicians' global impression (CGI), duration of severe mental illness, height, weight, BMI and waist/hip ratio. In addition, we calculated the risk using combined clinical predictors using the Leicester Practice Risk Score (LPRS) and the Topics Diabetes Risk Score (TDRS). Diabetes was defined by older criteria (impaired fasting glucose (IFG) or OGTT) as well as2010 criteria (IFG or OGTT or Glycated haemoglobin (HBA1c)) at conventional cut-offs.
Using the older criteria, 7.8% had diabetes (men: 6.3%; women: 10.3%). Using the new criteria, 10.2% had diabetes (men: 8.2%, women: 13.2%), representing a 30.7% increase (p = 0.02) in the prevalence of diabetes. Regarding biochemical predictors, conventional OGTT, IFG, and HbA1c thresholds used to identify newly defined diabetes missed 25%, 50% and 75% of people with diabetes, respectively. The conventional HBA1c cut-point of ≥6.5% (48 mmol/mol) missed 7 of 10 newly defined cases of diabetes while a cut-point of ≥5.7% improved sensitivity from 44.4% to up to 85%. Specific algorithm approaches offered reasonable accuracy. Unfortunately no single clinical factor was able to accurately rule-in a diagnosis of diabetes. Three clinical factors were able to rule-out diabetes with good accuracy namely: BMI, waist/hip ratio and height. A BMI < 30 had a 92% negative predictive value in ruling-out diabetes. Of those not diabetic, 20% had a BMI ≥ 30. However, for complete diagnosis a specific biochemical protocol is still necessary.
Patients with SMI maintained on antipsychotic medication cannot be reliably screened for diabetes using clinical variables alone. Accurate assessment requires a two-step algorithm consisting of HBA1c ≥5.7% followed by both FG and OGTT which does not require all patients to have OGTT and FG.</description><subject>Adult</subject><subject>Algorithms</subject><subject>Antipsychotic agents</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotics</subject><subject>Biochemistry</subject><subject>Biology and life sciences</subject><subject>Biomarkers</subject><subject>Criteria</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus - diagnosis</subject><subject>Diabetes Mellitus - epidemiology</subject><subject>Diabetes Mellitus - etiology</subject><subject>Diabetes Mellitus - metabolism</subject><subject>Diabetics</subject><subject>Diagnosis</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>Fasting</subject><subject>Female</subject><subject>Glucose</subject><subject>Glucose - metabolism</subject><subject>Glucose tolerance</subject><subject>Glucose tolerance test</subject><subject>Glycosylated hemoglobin</subject><subject>Health</subject><subject>Health risks</subject><subject>Health screening</subject><subject>Hemoglobin</subject><subject>Hemoglobins</subject><subject>Hip</subject><subject>Hospital patients</subject><subject>Humans</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Laboratory testing</subject><subject>Lipids</subject><subject>Male</subject><subject>Medical diagnosis</subject><subject>Medicine and Health Sciences</subject><subject>Mental disorders</subject><subject>Mental Disorders - complications</subject><subject>Mental Disorders - drug therapy</subject><subject>Mental health</subject><subject>Mentally ill persons</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Observational studies</subject><subject>Phenotype</subject><subject>Prevalence</subject><subject>Prospective Studies</subject><subject>Psychotropic drugs</subject><subject>Reproducibility of Results</subject><subject>Risk</subject><subject>Risk assessment</subject><subject>Risk factors</subject><subject>ROC Curve</subject><subject>Sensitivity and Specificity</subject><subject>Systematic review</subject><subject>Type 2 diabetes</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9tq3DAQhk1padK0b1BaQaHQi91KluXDTUsIPQQCgR4vhSyP11q01lYjp82T9fU6u9mEXWih-MLW6Jt_5F8zWfZU8LmQlXi9DFMcjZ-vwwhzngteVsW97Fg0Mp-VOZf3976PskeIS86VrMvyYXYkhRJSNfVx9vv74OzArHejs8YzM3asdcEOsNqu1xE6Z1OIyHAIk6ddYBNCx1JgaCPAyPoQWedMCwmQuZGtTXIwJmQ_XRoYQnRhQraiEAk670dAZBEsuCs3Lqhkcmu8tkNIzhJG9UggjG_ZKfMmLoCFlkSutkFSwDR114-zB73xCE9275Ps6_t3X84-zi4uP5yfnV7MbNnkadZXrS0KsFXBZatkp5RtZVcaC43qwZZkmxS8bnlfKZW3pZBEc1tbJfNSmUqeZM9vdNc-oN55jjrP60ZVvBA5Eec3RBfMUq-jW5l4rYNxehsIcaFNpD_zoGXHbSG6pi9MXfBWtKIWFpTc3IqSXJLWm121qSUjLFkWjT8QPdwZ3aAX4UrT3eeFqkngxU4ghh8TYPrHkXfUwtCp3NgHErMrh1afqqbJS0mdQ9T8LxQ93aY3qOt6R_GDhFcHCcQk-JUWZkLU558__T97-e2QfbnHDmB8GjD4adMPeAgWN6CNATFCf-ec4HozNLdu6M3Q6N3QUNqzfdfvkm6nRP4B-10WCg</recordid><startdate>20190912</startdate><enddate>20190912</enddate><creator>Mitchell, Alex J</creator><creator>Vancampfort, Davy</creator><creator>Manu, Peter</creator><creator>Correll, Christoph U</creator><creator>Wampers, Martien</creator><creator>van Winkel, Ruud</creator><creator>Yu, Weiping</creator><creator>De Hert, Marc</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6014-598X</orcidid></search><sort><creationdate>20190912</creationdate><title>Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study</title><author>Mitchell, Alex J ; Vancampfort, Davy ; Manu, Peter ; Correll, Christoph U ; Wampers, Martien ; van Winkel, Ruud ; Yu, Weiping ; De Hert, Marc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-f7bc44ec7403b53d55cb3d6ace95fec62103108b0f7552b61344e0c8c53265a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Algorithms</topic><topic>Antipsychotic agents</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotics</topic><topic>Biochemistry</topic><topic>Biology and life sciences</topic><topic>Biomarkers</topic><topic>Criteria</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus - diagnosis</topic><topic>Diabetes Mellitus - epidemiology</topic><topic>Diabetes Mellitus - etiology</topic><topic>Diabetes Mellitus - metabolism</topic><topic>Diabetics</topic><topic>Diagnosis</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>Fasting</topic><topic>Female</topic><topic>Glucose</topic><topic>Glucose - metabolism</topic><topic>Glucose tolerance</topic><topic>Glucose tolerance test</topic><topic>Glycosylated hemoglobin</topic><topic>Health</topic><topic>Health risks</topic><topic>Health screening</topic><topic>Hemoglobin</topic><topic>Hemoglobins</topic><topic>Hip</topic><topic>Hospital patients</topic><topic>Humans</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Laboratory testing</topic><topic>Lipids</topic><topic>Male</topic><topic>Medical diagnosis</topic><topic>Medicine and Health Sciences</topic><topic>Mental disorders</topic><topic>Mental Disorders - complications</topic><topic>Mental Disorders - drug therapy</topic><topic>Mental health</topic><topic>Mentally ill persons</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Observational studies</topic><topic>Phenotype</topic><topic>Prevalence</topic><topic>Prospective Studies</topic><topic>Psychotropic drugs</topic><topic>Reproducibility of Results</topic><topic>Risk</topic><topic>Risk assessment</topic><topic>Risk factors</topic><topic>ROC Curve</topic><topic>Sensitivity and Specificity</topic><topic>Systematic review</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mitchell, Alex J</creatorcontrib><creatorcontrib>Vancampfort, Davy</creatorcontrib><creatorcontrib>Manu, Peter</creatorcontrib><creatorcontrib>Correll, Christoph U</creatorcontrib><creatorcontrib>Wampers, Martien</creatorcontrib><creatorcontrib>van Winkel, Ruud</creatorcontrib><creatorcontrib>Yu, Weiping</creatorcontrib><creatorcontrib>De Hert, Marc</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mitchell, Alex J</au><au>Vancampfort, Davy</au><au>Manu, Peter</au><au>Correll, Christoph U</au><au>Wampers, Martien</au><au>van Winkel, Ruud</au><au>Yu, Weiping</au><au>De Hert, Marc</au><au>McKenna, Peter John</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2019-09-12</date><risdate>2019</risdate><volume>14</volume><issue>9</issue><spage>e0210674</spage><pages>e0210674-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>We aimed to investigate which clinical and metabolic tests offer optimal accuracy and acceptability to help diagnose diabetes among a large sample of people with serious mental illness in receipt of antipsychotic medication.
A prospective observational study design of biochemical and clinical factors was used. Biochemical measures were fasting glucose, insulin and lipids, oral glucose tolerance testing (OGTT), hemoglobin A1c, and insulin resistance assessed with the homeostatic model (HOMA-IR) were determined in a consecutive cohort of 798 adult psychiatric inpatients receiving antipsychotics. Clinical variables were gender, age, global assessment of functioning (GAF), mental health clinicians' global impression (CGI), duration of severe mental illness, height, weight, BMI and waist/hip ratio. In addition, we calculated the risk using combined clinical predictors using the Leicester Practice Risk Score (LPRS) and the Topics Diabetes Risk Score (TDRS). Diabetes was defined by older criteria (impaired fasting glucose (IFG) or OGTT) as well as2010 criteria (IFG or OGTT or Glycated haemoglobin (HBA1c)) at conventional cut-offs.
Using the older criteria, 7.8% had diabetes (men: 6.3%; women: 10.3%). Using the new criteria, 10.2% had diabetes (men: 8.2%, women: 13.2%), representing a 30.7% increase (p = 0.02) in the prevalence of diabetes. Regarding biochemical predictors, conventional OGTT, IFG, and HbA1c thresholds used to identify newly defined diabetes missed 25%, 50% and 75% of people with diabetes, respectively. The conventional HBA1c cut-point of ≥6.5% (48 mmol/mol) missed 7 of 10 newly defined cases of diabetes while a cut-point of ≥5.7% improved sensitivity from 44.4% to up to 85%. Specific algorithm approaches offered reasonable accuracy. Unfortunately no single clinical factor was able to accurately rule-in a diagnosis of diabetes. Three clinical factors were able to rule-out diabetes with good accuracy namely: BMI, waist/hip ratio and height. A BMI < 30 had a 92% negative predictive value in ruling-out diabetes. Of those not diabetic, 20% had a BMI ≥ 30. However, for complete diagnosis a specific biochemical protocol is still necessary.
Patients with SMI maintained on antipsychotic medication cannot be reliably screened for diabetes using clinical variables alone. Accurate assessment requires a two-step algorithm consisting of HBA1c ≥5.7% followed by both FG and OGTT which does not require all patients to have OGTT and FG.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>31513598</pmid><doi>10.1371/journal.pone.0210674</doi><tpages>e0210674</tpages><orcidid>https://orcid.org/0000-0001-6014-598X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1932-6203 |
ispartof | PloS one, 2019-09, Vol.14 (9), p.e0210674 |
issn | 1932-6203 1932-6203 |
language | eng |
recordid | cdi_plos_journals_2289570412 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS); PubMed Central; Free Full-Text Journals in Chemistry |
subjects | Adult Algorithms Antipsychotic agents Antipsychotic Agents - adverse effects Antipsychotic Agents - therapeutic use Antipsychotics Biochemistry Biology and life sciences Biomarkers Criteria Diabetes Diabetes mellitus Diabetes Mellitus - diagnosis Diabetes Mellitus - epidemiology Diabetes Mellitus - etiology Diabetes Mellitus - metabolism Diabetics Diagnosis Drug therapy Drugs Fasting Female Glucose Glucose - metabolism Glucose tolerance Glucose tolerance test Glycosylated hemoglobin Health Health risks Health screening Hemoglobin Hemoglobins Hip Hospital patients Humans Insulin Insulin resistance Laboratory testing Lipids Male Medical diagnosis Medicine and Health Sciences Mental disorders Mental Disorders - complications Mental Disorders - drug therapy Mental health Mentally ill persons Middle Aged Mortality Observational studies Phenotype Prevalence Prospective Studies Psychotropic drugs Reproducibility of Results Risk Risk assessment Risk factors ROC Curve Sensitivity and Specificity Systematic review Type 2 diabetes |
title | Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T06%3A27%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Which%20clinical%20and%20biochemical%20predictors%20should%20be%20used%20to%20screen%20for%20diabetes%20in%20patients%20with%20serious%20mental%20illness%20receiving%20antipsychotic%20medication?%20A%20large%20observational%20study&rft.jtitle=PloS%20one&rft.au=Mitchell,%20Alex%20J&rft.date=2019-09-12&rft.volume=14&rft.issue=9&rft.spage=e0210674&rft.pages=e0210674-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0210674&rft_dat=%3Cgale_plos_%3EA599263193%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2289570412&rft_id=info:pmid/31513598&rft_galeid=A599263193&rft_doaj_id=oai_doaj_org_article_3d0c41d9f4a840b1b181ce5338665303&rfr_iscdi=true |